New study tests Anti-Inflammatory drink to reverse frailty in seniors

NCT ID NCT07182292

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests whether combining a home exercise program with a daily anti-inflammatory nutritional supplement (Alisenoc™) can improve physical performance in frail, malnourished adults aged 75 and older. Participants will be randomly assigned to receive either the anti-inflammatory supplement or a standard supplement alongside the same exercise routine. The goal is to see if the special supplement reduces inflammation and helps rebuild strength and mobility over 12 weeks, with follow-ups up to a year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Alisenoc™ (anti-inflammatory nutritional supplement with olive oil polyphenols, omega-3s, leucine, and antioxidants)

What this could lead to

If successful, this could offer a practical, drug-free way to help frail older adults regain strength and independence.

What could go wrong

This is a relatively small, early-stage trial (158 people) testing a supplement, not a drug. Results may not apply to all older adults, and benefits could be modest.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALNUTRITION ELDERLY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Frailty Malnutrition nutritional deficiency disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••